Biobab AiBIO Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
11
Biobab AiBIO General Information
Description
Developer of bio-space voyager technology designed for efficient drug discovery for patients with intractable and rare diseases. The company's technology overcomes the limitations of existing X-ray crystallography technology by introducing cryo-EM cryogenic electron microscopy equipment ,and analyzing the three-dimensional structure of a new target protein, enabling clients to develop new drugs for innovative targets.
Contact Information
Website
www.baobabaibio.comCorporate Office
- 207 Posco Green Building, 2nd Floor
- Yonsei Univ, 85, Songdogwahak-ro, Yeonsu-gu
- Incheon, 21983
- South Korea
Corporate Office
- 207 Posco Green Building, 2nd Floor
- Yonsei Univ, 85, Songdogwahak-ro, Yeonsu-gu
- Incheon, 21983
- South Korea
Biobab AiBIO Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 24-Nov-2023 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 23-Oct-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 15-Mar-2021 | $14.3M | $14.9M | Completed | Generating Revenue | |
| 1. Corporate | 01-Apr-2019 | $661K | $661K | Completed | Startup |
Biobab AiBIO Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biobab AiBIO Patents
Biobab AiBIO Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024210578-A1 | Heterobicyclic compound and pharmaceutical composition comprising same | Inactive | 05-Apr-2023 | ||
| WO-2024019562-A1 | Heterobicyclic compound and pharmaceutical composition comprising same | Inactive | 21-Jul-2022 | ||
| WO-2022186608-A1 | Anticancer use of extract from stichopus japonicus gonads or compounds derived therefrom | Inactive | 02-Mar-2021 | ||
| WO-2021075645-A1 | Pharmaceutical composition for preventing or treating familial adenomatous polyposis, comprising niclosamide and metformin | Inactive | 16-Oct-2019 | ||
| US-11033518-B2 | Pharmaceutical composition containing niclosamide for treating axin-gsk3 interaction-related diseases | Active | 09-Jan-2017 | A61K31/167 |
Biobab AiBIO Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biobab AiBIO Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Korea AI Startup 100 | Accelerator/Incubator | |||
| BiiG WAVE | Accelerator/Incubator | |||
| AJU IB Investment | Venture Capital | Minority | ||
| Korea Development Bank | VC-Backed Company | Minority | ||
| LSK Investment | Venture Capital | Minority |
Biobab AiBIO FAQs
-
When was Biobab AiBIO founded?
Biobab AiBIO was founded in 2018.
-
Where is Biobab AiBIO headquartered?
Biobab AiBIO is headquartered in Incheon, South Korea.
-
What is the size of Biobab AiBIO?
Biobab AiBIO has 19 total employees.
-
What industry is Biobab AiBIO in?
Biobab AiBIO’s primary industry is Drug Discovery.
-
Is Biobab AiBIO a private or public company?
Biobab AiBIO is a Private company.
-
What is Biobab AiBIO’s current revenue?
The current revenue for Biobab AiBIO is .
-
How much funding has Biobab AiBIO raised over time?
Biobab AiBIO has raised $14.9M.
-
Who are Biobab AiBIO’s investors?
Korea AI Startup 100, BiiG WAVE, AJU IB Investment, Korea Development Bank, and LSK Investment are 5 of 11 investors who have invested in Biobab AiBIO.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
